Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CX5461 in advanced solid tumors
NCT02719977Phase 1Completed
- Sponsor
- Canadian Cancer Trials Group
- Start
- Jun 2016
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pidnarulex in solid tumor and breast cancer, sponsored by Canadian Cancer Trials Group. Primary endpoint: Recommended Phase II Dose at 12 months. Started Jun 2016; status: completed.
02
Drugs
pidnarulex
03
Conditions
solid tumorbreast cancer
Beyond the preview
Go deeper on NCT02719977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02719977.